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Abstract 
The transport of the molecules inside cells is a very important topic, especially in Drug Metabolism. The 
experimental testing of the new proteins for the transporter molecular function is expensive and inefficient due to 
the large amount of new peptides. Therefore, there is a need for cheap and fast theoretical models to predict the 
transporter proteins. In the current work, the primary structure of a protein is represented as a molecular Star 
graph, characterized by a series of topological indices. The dataset was made up of 2,503 protein chains, out of 
which 413 have transporter molecular function and 2,090 have no transporter function. These indices were used 
as input to several classification techniques to find the best Quantitative Structure Activity Relationship (QSAR) 
model that can evaluate the transporter function of a new protein chain. Among several feature selection 
techniques, the Support Vector Machine Recursive Feature Elimination allows us to obtain a classification model 
based on 20 attributes with a true positive rate of 83% and a false positive rate of 16.7%. 
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l. INTRODUCTION 
The transport proteins are vital to the growth and life of all living things due to their function of 
moving the molecules within an organism, including the administrated drugs. There are several 
different kinds of transport proteins such as carrier proteins that are involved in the movement across 
a biological membrane of ions, small molecules, or macromolecules, such as another protein [1]. 
Each carrier protein is designed to recognize only one substance or one group of very similar 
substances. Therefore, specific diseases are correlated with the errors in transport proteins. Another 
example of transport protein is the vesicular transporter, a transmembrane or membrane associated 
protein that regulates or facilitates the movement by vesicles of the contents of the cell.  
 
During the 1950s, the researchers reported in literature that the movement of a number of 
substances, both uncharged and ionic, across cell membranes was catalyzed by specific proteins. 
Transporters are divided into passive and active transporters: passive transporters (facilitated 
transporters) allow passage of solutes (e.g., glucose, amino acids, urea) across membranes down their 
electrochemical gradients; active transporters create ion/solute gradients across membranes, utilizing 
diverse energy-coupling mechanisms. 
 
Several mechanisms of transport have been presented. First, the electrochemical potential 
gradients of cations were observed, which allow the transport of nonelectrolytes against their 
concentration gradients [2, 3]. Another mechanism is used by the proteins called ion pumps that are 
driven by the energy of hydrolysis of ATP through the action of specific adenosinetriphosphatases 
[4], in particular for Na+ and K+, for Ca2+ and for H+ and K+ [5, 6]. Other sources of energy for 
transport, other than hydrolysis of A TP, were discovered: light in halobacteria [7], oxidative 
decarboxylation in various bacteria [8], terminal oxidation of substances in inner mitochondrial and 
chloroplast membranes, etc. The discoveries of selective channels in cell membranes, such as would 
allow the passage of Na+, K+ and Ca2+ ions across nerve plasma membranes and a number of 
intracellular membranes in other types of cells, without any energy supply being required and hence 
no accumulation of such ions against their electrochemical potential gradient being achieved. Another 
transport pathway was discovered that not only did not require energy coupling but it was either fully 
or in great measure nonselective, sometimes in the absence of proteins. Therefore, a Transporter 
Classification (TC) system was defined during the 1990's, in analogy with the Enzyme Commission 
(EC) system for classification of enzymes. The difference consists in the fact that the TC system 
incorporates. both functional and phylogenetic information [9]. The TC system provides descriptions, 
TC numbers, and examples of over 600 families of transport proteins [10]. Transport systems are 
classified on the basis of five criteria, and each of these criteria corresponds to one of the five 
numbers or letters within the TC# for a particular type of transporter. Thus, a TC# normally has the 
following five components: V.W.X.Y.Z. V (a number) corresponds to the transporter class such as 
channel, carrier/porter, primary active transporter, group translocator or transmembrane electron flow 
carrier; W (a lettter) corresponds to the transporter subclass which in the case of primary active 
transporters refers to the energy source used to drive transport; X (a number) corresponds to the 
transporter family (superfamily); Y (a number) corresponds to the subfamily in which a transporter is 
found, and Z corresponds to a specific transporter with a particular substrate or range of substrates 
transported. The TC database (TCDB) can be accessed at http://www.tcdb.org/ [11, 12]. TCDB is a 
curated database of factual information from over 10,000 published references and it contains about 
5,600 unique protein sequences. Another transporter collection consists of TransportDB, a relational 
database describing the predicted cytoplasmic membrane transport protein complement for organisms 
whose complete genome sequence is available at http://www.membranetransport.org/ [13-16]. The 
RCSB Protein Data Bank (http: //www.rcsb.org) is classifying the transporter proteins using the same 
TC system in: (1) Channels/Pores, (2) Electrochemical Potential-driven Transporters, (3) Primary 
Active Transporters, (4) Group Translocators, (5) Transmembrane Electron Carriers, (8) Accessory 
Factors Involved in Transport and (9) Incompletely Characterized Transport Systems. The gene 
ontology for the transport proteins (G0:0015031) is presented in (Fig. l) and it is available online at 
http ://www.yeastrc.org.  
  
 
 
 
Fig. (1). Transport protein gene ontology (GO:OOI5031 ). 
Drug transporters (DTs) are among the many ATPasetype active transporters germane to the 
pharmaceutical industry. DTs pump drug molecules out of the (primarily) liver cells, in order to 
maintain low/nontoxic concentrations of a drug molecule inside cells and in the body. Consequently, 
if the DT activity is over increased, the efficacy of the drugs can be reduced. The drug toxicity and 
drug clearance are two common reasons for a drug to be withdrawn from the market, costing 
developers anywhere from hundreds of millions to billions of dollars. Therefore, eliminating these 
concerns can greatly reduce the cost of and time to market approval. The authors created liver cells 
with high levels of the enzyme responsible for the liver's metabolic properties. By increasing the 
levels of oxygen to these cultures, they were able to predict clearance rates from drugs as diverse as 
anxiolytics and anticonvulsant weeks in advance [17].  
 
The importance of drug transport and drug transporters goes beyond the individual transporter 
proteins and beyond the assays to measure their activity. Increased research efforts to characterize 
current transporters and identify new ones are vital to an understanding of drug resistance as well as 
to determining drug efficacy and safety, in general. Concomitant development of drug transporter 
assays is equally important in meeting these challenges. Drugs that are substrates or inhibitors of drug 
transporters have been implicated in drug-drug interactions. Thus, the 2012 FDA DDI draft guidance 
[18] and the 2012 EMA guideline on investigation of drug interactions [19] mention several specific 
transporters to investigate and assay conditions to follow. In addition, the European Drug Initiative 
on Channels and Transporters (EDICT, http://www.edict-project.eu) [20] is helping to determine the 
structures of clinically significant membrane protein channels and transporters for the initial 
development of drugs.  
 
Drug transporters play an important role in the absorption, distribution, and excretion (ADE) of 
many drugs [21]. It was pointed out the significant differences between rodents, dog, monkey, and 
human in the substrate specificity, tissue distribution, and relative abundance of transporters. These 
differences complicate cross-species extrapolations, which is important when attempting to predict 
human pharmacokinetics (PK) of drug candidates and assess risk for drug-drug interactions (DDIs). 
The quantitative knowledge of species differences of transporters, especially at the protein and 
functional level is still limited. Therefore, there is a challenge to extrapolate and integrate data from 
both preclinical species and humans to quantitatively predict the impact of transporters on drug 
absorption, disposition, and drug-drug interactions. The penetration of drugs into the human brain 
through the blood-brain barrier (888) represents a major obstacle to the development of successful 
neuropharmaceuticals. This restricted permeability is due to the delicate intercellular junctions, efflux 
transporters and metabolizing enzymes present at the BBB [22]. The pharmaceutical industry and 
academic research rely heavily on permeability studies conducted on animals and in vitro models of 
the BBB. Different drug transporters are involved in specific biological processes in several organs 
such as brain (ex.: in epilepsy, the P-glycoprotein and multidrug resistance associated proteins) [23], 
intestine [24], kidney [25, 26], placenta [27], sexual gonads [28] or central nervous system [29].  
 
The human transport proteins for drugs and endogenous substances in plasma membrane domains 
of intestinal epithelia, hepatocytes, kidney proximal tubules and brain capillary endothelial cells [30] 
are depicted in (Fig. 2):  
 
a) The intestinal epithelia contain in their apical (luminal) membrane several uptake transporters, 
including one or more members of the organic anion-transporting polypeptide (OATP) family, 
peptide transporter 1 (PEPT 1; SLCI5Al), ileal apical sodium/bile acid co-transporter (ASBT; 
SLC10A2), and monocarboxylic acid transporter 1 (MCTl; SLC16AI). The apical ATP-dependent 
efflux pumps include multidrug resistance protein 2 (MRP2; ABCC2), breast cancer resistance 
protein (BCRP; ABCG2) and P-glycoprotein (P-gp; MDRl, ABCBl). The baso lateral membrane 
of intestinal epithelia contains organic cation transporter 1 (OCTl; SLC22Al), heteromeric organic 
solute transporter (OSTα-OSTβ) and MRP3 (ABCC3).  
 
b) Human hepatocyte uptake transporters in the basolateral (sinusoidal) membrane include the 
sodium/taurocholate co-transporting peptide (NTCP; SLCIOAl), three members of the OATP 
family - OATPlBl (SLCOJBI), OATPIB3 (SLCOJB3) and OATP2Bl (SLC02BI), organic anion 
transporter 2 (OAT2; SLC22A7) and OAT7 (SLC22A9), and OCTl. Efflux pumps in the 
hepatocyte basolateral membrane include MRP3, MRP4 (ABCC4) and MRP6 (ABCC6). Apical 
(canalicular) efflux pumps of the hepatocyte comprise P-gp, bile-salt export pump (BSEP or 
SPGP; ABCBil), BCRP (ABCG2) and MRP2. In addition, multidrug and toxin extrusion protein 
1 (MATE1; SLC47 Al) is located in the apical hepatocyte membrane.  
 
c) Kidney proximal tubules contain OAT4 (SLC22AII), urate transporter 1 (URATJ ; SCL22Al2), 
PEPTl and PEPT2 (SLCI5A2), MRP2 and MRP4, MATE! and MATE2-K (SLC47A2), P-gp, 
organic cation/ergothioneine transporter (OCTN 1; SLC22A4), and organic cation/carnitine 
transporter (OCTN2; SLC22A5) in the apical (luminal) membrane. Basolateral uptake 
transporters in proximal tubule epithelia include OATP4CI (SLC04Cl), OCT2, OATl, OAT2 and 
OAT3 (SLC22A8).  
 
d) Blood- brain barrier: Apical (luminal) transport proteins of brain capillary endothelial cells 
contributing to the function of the blood- brain barrier include the uptake transporters OATP1A2 and 
OATP2B1, the efflux pumps P-gp, BCRP, MRP4 and MRP5 (ABCC5).  
  
 
 
 
Fig. (2). The human transport proteins for drugs and endogenous substances. 
The localization of transporters to particular membranes and tissues is sometimes controversial 
and, consequently, the International Transporter Consortium is showing only the localization of 
transporters for which good evidence exists.  
 
The importance of transporters in drug metabolism creates the necessity of cheap and fast 
theoretical models to predict the transporter function for a new amino acid sequence. This model can 
reduce the number of molecules for tests in different experiments and increase the success rates when 
molecules are tested looking for transporters. The current work is putting forward the first theoretical 
model for transporter prediction using the primary sequences of protein chains. The obtained model is 
a Quantitative Structure - Activity Relationship (QSAR) [31) between primary amino acid structure 
of the protein chain and the transporter molecular function. The base of the model consists of the 
topological indexes (TIs) of macromolecular Star graphs with amino acids as nodes. The graph theory 
is a branch of mathematical chemistry and it is currently an intense area of research, generating new 
information regarding DNN/proteins (represented as graphs) [32-35]. The QSAR models are found 
using several Machine Leaning techniques of classification [36].  
 
The QSAR models have been intensively used with applications in different problems [37, 38] 
such as the prediction of analgetic agents [39], anti-cancer agents [40-42], anti-inflamatory agents 
[43], taxane analogues in colon cancer [44], anti-parasitic drugs [45, 46], anti-Alzheimer agents [47] 
or human breast biomarkers [48]. The graphs/complex networks have been used to graphically 
process information from molecules (ex: drugs, proteins, nucleic acids) [49-55] to biological systems 
(ex: parasite-host networks, protein-protein interaction network, gene-gene interaction networks) [56-
58].  
  
Protein models obtained with Star Graph TIs have been published and permitted to prediction of 
cancer [59], DNA promoters [60], human breast and colon cancer-related proteins [61), 
natural/random proteins [62] or anti-oxidant proteins [63]. The kernel-based machine learning 
protocols have been previously used to predict DNA-binding proteins [64], the protein function [65, 
66], the protein fold [67], the protein functional sites [68], and the drug - protein interaction [69].  
 
In the current work, the authors present the first transport/ non-transport protein classification 
model based on embedded/non-embedded Star Graph TIs including the trace of connectivity 
matrices, Harary number, Wiener index, Gutman index, Schultz index, Moreau-Broto indices, 
Balaban. distance connectivity index, Kier-Hall connectivity indices and Randic connectivity index. 
Several feature selection methods were tested and the best model was obtained with the Support 
Vector Machine Recursive Feature Elimination technique.  
2. MATERlALS AND METHODS  
The description of the methodology followed in this work is presented in (Fig. 3). The database 
consists of amino acid sequences (primary structure) of transporter and nontransporter proteins in F 
ASTA format. In the first step, the sequences of amino acids are transformed with S2SNet [70] into 
topological indices of the protein Star graphs. The resulting numbers that characterized each graph 
(protein graphical representation) are then used in Weka [71] to find the best QSAR classification 
model with Machine Learning methods. A final model is suggested to predict the transporter 
molecular function for new amino acid sequences .  
  
 
 
 
Fig. (3). General flow chart for obtaining a transporter protein classification model using the topological indices of the protein 
sequence Stargrapbs. 
In statistics, two events are independent when the fact that one occurs does not modify the 
probability of the other one. An observation is normal when its behavior follows a normal or 
Gaussian distribution with a certain value of mean and variance. In order to respect this independence 
condition, the authors have tested the different classification techniques using 10-fold cross-
validation to split data [72]. Dataset is randomly partitioned into 10 equal-sized bins. 9 bins were 
picked 10 times to train the models and the remaining bin was used to test them, each time leaving 
out a different bin.  
 
The performance of prediction models for a two-class problem (i.e. transport or not transport) is 
typically evaluated using a confusion matrix. There are several numbers of well-known accuracy 
measures for a two-class classifier in the literature, such as: classification rate, precision, sensitivity, 
specificity, F-measure, Area Under the Receiver Operating Characteristic (ROC) Curve, etc. An 
experimental comparison of performance measures for classification could be found in [73]. The 
higher the precision, the less effort wasted in testing and inspection; and the higher the recall, the 
fewer defective modules go undetected. However, there is a tradeoff between precision and recall and 
therefore a combination of both is needed in a single efficiency measure, known as F-measure, which 
considers both precision and recall equally important [74]. Jin et al. [75] suggested that AUC is a 
better measure than accuracy when comparing classifiers and in general.  
 
The ROC is also known as a relative operating characteristic curve, because it is a comparison of 
two operating characteristics (a true positive rate and a false positive rate) as the criterion changes 
[76]. ROC curve is a graphical plot which illustrates the performance of a binary classifier system as 
its discrimination threshold is varied. It is created by plotting the fraction of true positives out of the 
positives (TP Rate = true positive rate) vs. the fraction of false positives out of the negatives (FP Rate 
= false positive rate), at various threshold settings. TP Rate is also known a~ sensitivity, and FP Rate 
is one minus the specificity or true negative rate. ROC analysis provides tools to select possibly 
optimal models and to discard suboptimal ones independently of (and prior to specifying) the cost 
context or the class distribution. ROC analysis is related in a direct and natural way to cost/benefit 
analysis of diagnostic decision making.  
 
The test set is divided randomly into two parts (training and validation) extracting a total of 20% 
of the training data. The objective of this paper is to evaluate the ability of SVM in predicting 
transport/non-transport proteins classification.  
 
Several experiments have been performed in order to select the best models. The final compared 
models are a linear classifier techniques: LIBLINEAR (LL) [77], a neural network technique - 
Multilayer Perceptrons (MLP), a Bayesian technique - Naïve Bayes, and two tree-structured classifier 
techniques - Random Forests (RF) and J48. The parameters for each of the models were initialized 
mostly with the default setting of the Weka toolkit and using the experimenter, they were optimized 
in order to obtain the best parameter combination for each model.  
2.1. Protein Set  
The current work is based on datasets extracted from two protein databases. The sets of protein 
primary sequences are made up of 413 proteins with the transporter molecular function and 2,090 
non-transporters. The transporter protein FASTA sequences (positive group) have been downloaded 
from the Protein Databank [78], the "Transporter (GO ID5215)" list obtained with the "Molecular 
Function Browser" in the "Advanced Search Interface" (protein identity cut-off= 30%). The negative 
group was created using the PISCES CulledPDB [79] list of proteins (downloaded on November 16
th
, 
2012) with identity (degree of correspondence between two sequences) less than 20%, resolution of 
1.6 A and R-factor 0.25 (non-transporter proteins with any other possible biological function). The 
sequence identities for PDB sequences in the PISCES server (http://dunbrack.fccc.edu/PISCES.php) 
have been determined using Combinatorial Extension (CE) structural alignment [80]. This server 
used a Z-score of 3.5 as the threshold to accept possible evolutionary relationships. PISCES' 
alignments are local, so that two proteins which share a common domain with sequence identity 
above the threshold are not both included in the output lists. No list has been post-filtered for any 
source organism.  
2.2. Star Graph Topological lndices  
The protein primary scquences were graphically transformed into Star Graphs, where the amino 
acids are the vertices (nodes), connected in a specific sequence by the peptide bonds. The Star Graph 
is a special type of tree with N vertices where one has got N-1 degrees of freedom and the remaining 
N-1 vertices have got one single degree of freedom [81] . Each of the 23 possible branches ("rays") of 
the star contains the same amino acid type and the star centre is a non-amino acid vertex [82]. We 
used 20 groups for the standard amino acids (A, R, N, D, C, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y, 
V), 2 groups with two nonstandard ones (U, O) and 1 group with four ambiguous amino acids (B, Z, 
J, X). Thus, the following information of the protein primary structure is encoded into the Star Graph 
connectivity: amino acid type, sequence and frequency.  
  
A protein can be represented by diverse forms of graphs, which can be associated with distinct 
distance matrices. The best method to create a standard Star Graph is described subsequently: each 
amino acid/vertex holds the position in the original sequence and the branches are labeled 
alphabetically by the 3-letter amino acid code. The graph is embedded if the initial sequence 
connectivity in the protein chain is included.  
 
Graphs are compared using the corresponding connectivity matrix, distance matrix and degree 
matrix. These matrices and the normalized ones are the basis of the TIs calculation. The calculation 
of the Star Graph TIs for the amino acid sequences was performed using the Sequence to the Star 
Networks (S2SNet) application [70]. This tool was programmed in Python/wxPython [83] and has a 
Graphviz [84] plotting back-end. The TIs are calculated using the embedded and non-embedded Star 
graphs, without weights, using Markov normalization and a power of matrices/indices (n) up to 5. 
The following list depicts the S2SNet TIs [85]: 
 
 Trace of the n connectivity matrices (Trn): 
 
𝑇𝑟𝑛 = ∑ (𝑀
𝑛)𝑖𝑖 ,
𝑖
 (1) 
 
where n = 0 – power limit, M = graph connectivity matrix (i*i dimension); ii = ith diagonal 
element; 
 
 Harari number (H): 
 
𝐻 = ∑ 𝑚𝑖𝑗/𝑑𝑖𝑗 ,
𝑖<𝑗
 (2) 
 
where dij are elements of the distance matrix and mij are elements of the M connectivity matrix; 
 
 Wiener index (W): 
 
𝑊 = ∑ 𝑑𝑖𝑗 ,
𝑖<𝑗
 (3) 
 
 Gutman topological index (S6): 
 
𝑆6 = ∑ 𝑑𝑒𝑔𝑖 ∗  𝑑𝑒𝑔𝑗/ 
𝑖𝑗
𝑑𝑖𝑗 , (4) 
 
where degi are the elements of the degree matrix; 
 
 Schultz topological index (nontrivial part) (S): 
 
𝑆 = ∑ (𝑑𝑒𝑔𝑖 + 𝑑𝑒𝑔𝑗) 
∗ 𝑑𝑖𝑗 ,
𝑖<𝑗
 (5) 
 
 Balaban distance connectivity index (J): 
 
𝐽 = (𝑒𝑑𝑔𝑒𝑠 − 𝑛𝑜𝑑𝑒𝑠 + 2) ∗ ∑ 𝑚𝑖𝑗  
∗sqrt
𝑖<𝑗
(∑ 𝑑𝑖𝑘  
∗ ∑ 𝑑𝑘𝑗
𝑘𝑘
), (6) 
 
where nodes + 1 = AA numbers/node number in the Star Graph + origin, ∑ 𝑑𝑖𝑘 ,𝑘  k--,d-ik...is the 
node distance degree; 
  
 Kier-Hall connectivity indices (nX): 
 
 0𝑋 = ∑ 1
𝑖
 / sqrt(𝑑𝑒𝑔𝑖), (7) 
  
 2X = ∑ mij  
∗mjk  /  sqrt(degi  
∗degj  
∗degk)
i<j<k
, (8) 
  
 3X = ∑ mij 
∗mjk
i<j<k<m
 ∗mkm / sqrt(degi 
∗degj 
∗degk 
∗degm), (9) 
  
 4X = ∑ mij 
∗mjk 
∗mkm 
∗mmo / sqrt(degi 
∗degj 
∗degk 
∗degm 
∗dego),
i<j<k<m<o
 (10) 
  
 5X = ∑ mij 
∗mjk 
∗mkm 
∗mmo  
∗moq
i<j<k<m<o<q
/ sqrt(degi 
∗degj 
∗degk 
∗degm 
∗dego 
∗degq), 
(11) 
 
 Randic connectivity index (1X): 
 
 1𝑋 = ∑ 𝑚𝑖𝑗/
𝑖𝑗
sqrt(𝑑𝑒𝑔𝑖  
∗𝑑𝑒𝑔𝑗), (12) 
 
These Tls and other derivate ones will be used in the next step to create an antioxidant 1 non-
antioxidant classification model using Machine Leaming methods.  
2.3. Support Vector Machines  
Vapnik introduces Support Vector Machines (SVMs), a kernel based learning algorithms, in the 
late 1970s on the foundation of a statistical learning theory [86], using the Structural Risk 
Minimization (SRM) principle which minimizes the generalization error (i.e. true errors on unseen 
examples). The basic implementation deals with two-class problems in which data are separated by a 
hyperplane defined by a number of support vectors. This hyperplane separates the positive from the 
negative examples, to be oriented in such a way that the distance between the boundary and the 
nearest data point in each class is maximal; the nearest data points are used to define the margins, 
known as support vectors [87]. Support vectors are a subset of training data used to define the 
boundary between the two classes. These classifiers have also proven to be exceptionally efficient in 
classification problems of higher dimensionality [88]. SVM uses different nonlinear kernel functions, 
like polynomial, sigmoid and radial basis function (RBF) which yields better prediction performance 
[89], where the nonlinear SVM maps the training samples from the input spaces into a higher 
dimensional feature space via a mapping function [87, 90]. Gunn introduced SVMs as an effective 
technique for solving both classification and regression problems. The main characteristics of SVMs 
[91] are the following: 
 
 The ability of SVMs to learn can be independent of the feature space dimensionality under small 
training sample conditions.  
 
 SVMs are formulated as a quadratic programming problem; it gives a global optimum solution. 
 
 They are robust to outliers. Using the margin parameter C, SVMs control the misclassification 
error and prevent the effect of outliers.  
 
 They can model nonlinear functional relationships that are difficult to model with other 
techniques.  
  
3. RESULTS  
The dataset used in this paper is made up of 2,503 protein sequences, out of which 413 have 
proved to have the molecular function of transporters (positive group) with maximum identity of 
30%. The remaining 2,090 proteins (negative group) are sequences from the CulledPDB server with 
identity less than 20%, without the transporter function. In order to resample this dataset, a synthetic 
minority oversampling technique [92] can be applied in Weka. These protein sequences have been 
processed with the S2SNet application [70] in order to obtain the different topological indexes used 
in this study. Specifically, from each sequence 42 attributes are calculated for the corresponding 
embedded/nonembedded Star Graph as shown in Table l. 
Table l. Attributes Extracted from Embedded/Non-Embedded Star Graph. 
 Attributes (Tis) 
 Non-embedded  Embedded 
    
Sh Sh0,Shl, Sh2, Sh3,Sh4, Sh5  eSh0, eShl, eSh2,eSh3, eSh4, eSh5 
Tr Tr0, Tr2, Tr4  eTr0, eTr2, eTr3, eTr4, eTr5 
X X0, X1R, X2, X3 , X4 , X5  eX0, eX1R, eX2, eX3, eX4, eX5 
Remaining H, W, S6, S, J  eH, eW, eS6, eS, eJ 
    
 
Table 2 shows the results of the different classification models tested, considering all the 
attributes extracted from tl1e Star Graph (42 attributes). This table presents for each model the 
classification scores obtained for the different classes, true and false positive rates (TP/FP Rates), as 
well as F-measure, the ROC values for both training and validation and the number of attributes that 
were considered. The SVM implementation [93] in Weka seems to be the best model because it 
obtains an AUC-ROC value of 0.911 with 42 features. For this model, the regularization parameter is 
set to 10; the kernel function used was Gaussian (RBF) with gamma set to 10. 
Table 2. Classification Model Results. 
Training  Validation 
 
TP 
Rate 
FP 
Rate 
F-Measure 
ROC 
Area 
 
TP 
Rate 
FP 
Rate 
F-Measure ROC Area 
No. of 
Features 
           
SVM 0.833 0.167 0.833 0.909  0.832 0.167 0.832 0.911 42 
MLP 0.607 0.393 0.593 0.633  0.649 0.359 0.643 0.677 42 
NB 0.603 0.396 0.595 0.628  0.614 0.395 0.606 0.654 42 
RF 0.810 0.190 0.809 0.891  0.812 0.185 0.812 0.898 42 
LL 0.616 0.384 0.613 0.616  0.655 0.350 0.653 0.653 42 
J48 0.682 0.318 0.682 0.734  0.691 0.310 0.691 0.739 42 
           
 
In order to reduce the number of features necessary to classify proteins in transport/non-transport, 
we performed three types of techniques for feature selection.  
  
Technique 1: In Table 1, we presented the grouping of the variables corresponding to the 
embedded and non-embedded Star graphs. In addition, each one of them is divided into different 
subsets: a subset called Sh, which includes the attributes related to the entropy; a subset called Tr, 
which includes the attributes related to the traces; a subset called X, which includes the attributes 
related to the polygon indexes; and the remaining attributes regarding the general shape of the 
graphs. We have performed different experiments with these subsets separately and in combination 
with the others with the best technique (SVM) shown in Table 2. Results are shown in Table 3. Using 
22 variables, all embedded, SVM obtained an AUC-ROC value of 0.894 with a false positive rate of 
0.18. Using 20 variables, Tr and X subsets, the model obtained an AUC-ROC value of 0.89 with a 
false positive rate of 0.166. Both are very close to the best result comparing the AUC-ROC values, 
but both also have a slightly higher false positive rate.  
Table 3. Feature Selection Grouping by Membership and Using Weka 's Classifler Subset Evaluator. 
Training  Validation 
 
TP 
Rate 
FP 
Rate 
F-Measure 
ROC 
Area 
 
TP 
Rate 
FP 
Rate 
F-Measure 
ROC 
Area 
Feat. 
No. 
           
All 0.833 0.167 0.833 0.909  0.832 0.167 0.832 0.911 42 
All emb 0.831 0.199 0.801 0.873  0.818 0.180 0.818 0.894 22 
All non-emb 0.708 0.292 0.708 0.767  0.711 0.287 0.711 0.765 20 
Sh emb 0.614 0.386 0.613 0.660  0.632 0.371 0.631 0.688 6 
Sh non-emb 0.636 0.364 0.636 0.680  0.649 0.355 0.647 0.702 6 
Sh & Tr emb 0.768 0.232 0.768 0.844  0.785 0.212 0.784 0.861 11 
Sh & Tr non-
emb 
0.591 0.322 0.621 0.701  0.652 0.351 0.651 0.705 9 
Sh & Tr 0.840 0.231 0.812 0.870  0.806 0.194 0.806 0.874 20 
Sh 0.650 0.350 0.650 0.703  0.659 0.343 0.659 0.724 12 
Sh & X emb 0.655 0.345 0.655 0.712  0.650 0.352 0.650 0.713 12 
Sh & X non-
emb 
0.673 0.327 0.673 0.730  0.686 0.315 0.686 0.736 12 
Sh & X 0.718 0.282 0.718 0.781  0.723 0.276 0.723 0.787 24 
Tr emb 0.736 0.264 0.736 0.799  0.741 0.257 0.741 0.818 5 
Tr non-emb 0.606 0.394 0.606 0.641  0.617 0.386 0.617 0.658 3 
Tr 0.757 0.243 0.756 0.822  0.770 0.227 0.770 0.843 8 
Tr & X emb 0.776 0.224 0.776 0.841  0.793 0.205 0.793 0.866 11 
Tr & X non-
emb 
0.639 0.361 0.639 0.701  0.646 0.355 0.646 0.703 9 
Tr & X 0.813 0.187 0.814 0.885  0.832 0.166 0.831 0.890 20 
X emb 0.630 0.370 0.630 0.676  0.627 0.377 0.625 0.674 6 
X non-emb 0.633 0.367 0.633 0.683  0.634 0.369 0.633 0.687 6 
X 0.691 0.332 0.681 0.720  0.664 0.335 0.664 0.723 12 
           
 
Technique 2: In Weka, there is a classifier subset eva1uator. This technique evaluates attribute 
subsets on training data or a separate hold out testing set using a 1 0-fold cross validation, and it uses 
a classifier to estimate the merit of a set of attributes. In this case, this technique obtained a solution 
with 27 variables, an AUC-ROC value of 0.909 and a false positive rate of 0.161. In this case, the 
solution has an AUC-ROC value very similar to the best model in Table 2 and it uses only 27 
variables. Results are shown in Table 4.  
Table 4. Feature Selection Results Using Technique 2. 
Training  Validation 
 TP 
Rate 
FP 
Rate 
F-Measure ROC 
Area 
 TP 
Rate 
FP 
Rate 
F-Measure ROC 
Area 
No. of 
Features 
           
SVM 0.827 0.173 0.827 0.902  0.866 0.161 0.866 0.909 27 
           
The final model contains the following embedded and non-embedded Tls: Sh0, Sh1, Sh3, Sh4, 
Tr0, Tr2, H, W, S6, S, J, X1R, X3, X4, X5, eSh2, eSh5, eTr0, eTr2, eTr3, eTr4, eTr5, eH, eS6, eX1R, 
eX3 and eX5.  
 
Technique 3: SVM seems to be the fittest model according to results in Table 2. There is a 
technique for feature selection using SVMs known as Support Vector Machine Recursive Feature 
Elimination (mSVM-RFE), the output is a feature ranking. SVM-RFE is an iterative algorithm that 
works backwards an initial set of features [94]. At each round this algorithm fits a simple linear 
SVM, ranks the features based on their weights in the SVM solution and eliminates the feature with 
the lowest weight. mSVM-RFE [95] extends this idea by using resampling techniques at each 
iteration to stabilize the feature ranking; in this work we use a 10-fold cross validation to this end. We 
estimate the generalization error and use it because when feature selection is performed on a data set 
with many features, it will pick some features that will be generalized, but it will also pick some 
useless features. Feature ranking is shown in Table 5. In this case, the features will give good 
performance if the error is estimated from this training set itself; Guyon et al. originally made this 
mistake, but this issue is outlined in Ref. [96]. Finally, we estimate the generalization error we can 
expect if we were to train a final classifier using the ranking of features for each of the 10 training 
sets. Generalization error for 20 variables is shown in (Fig. 4).  
Table 6. mSVM-RFE Feature Selection Results. 
Average Ranking Value Attributes 
  
Lower than or equal to 15 
eTr4(5.1), eX5(5.1), J(5.2), eTr5(5.2), eTr3(5.7), Shl(8.0), X5(8.8), XIR(9.2), eJ(10.0), 
eShl(10.9), X0(12.5), S6(13.2), eSh2(13.3), Tr2(14.7), eTr2(15.0) 
Higher than 15 
eS(16.9), Sh0(18.9), Tr0(19.8), W(19.9), eH(20.7), eX3(22.7), Tr4(23.5), Sh5(24.5), Sh4(25.1), 
eX2(25.1), eSh4(26.2), Sh2(26.3), eSh3(26.9), eW(27.7), eSh0(29.6), eTr0(30.3), X3(30.9), 
X2(31.9), S(32.0), eX4(33.0), eX0(33.8), eS6(33.9), eX1R(33.9), eSh5(35.3), H(35.9), 
X4(37.1), Sh3(39.3) 
  
 
 
 
 
Fig. (4). Generalization error for the 20 first attributes in the ranking. 
  
mSVM-RFE feature selection used a Radial Basis Function (RBF) kernel SVM and a grid search 
for SVM parameters (cost and gamma) and it was carried out a 10-fold cross validation error 
estimation. The optimal parameters were used to train the SVM on the entire training set and the 
generalization error was determined by predicting the corresponding test set. Results are shown in 
Table 6. We evaluate the top 10, 15, 20 and 2 7 features from the ranking and the top 10, 15 features 
from the embedded and non-embedded feature groups. We use R [97], a free software environment 
for statistical computing and graphics and an mSVM-RFE implementation 
(http://www.colbyimaging.com/wiki/statistics/msvm-rfe). 
Table 6. mSVM-RFE Feature Selection Results. 
  Training  Validation 
No. of 
Attr. 
Type 
TP 
Rate 
FP 
Rate 
F-Measure 
ROC 
Area 
 
TP 
Rate 
FP 
Rate 
F-Measure 
ROC 
Area 
           
10 Rank 0.798 0.203 0.797 0.870  0.813 0.183 0.813 0.881 
15 Rank 0.808 0.192 0.808 0.884  0.824 0.173 0.824 0.894 
20 Rank 0.809 0.191 0.809 0.888  0.830 0.167 0.830 0.900 
27 Rank 0.824 0.176 0.824 0.899  0.836 0.162 0.836 0.906 
10 Embedded 0.779 0.221 0.778 0.845  0.806 0.191 0.806 0.867 
15 Embedded 0.785 0.215 0.785 0.858  0.807 0.191 0.807 0.883 
10 
Non-
embedded 
0.667 0.333 0.677 0.730  0.684 0.314 0.684 0.743 
15 
Non-
embedded 
0.694 0.306 0.694 0.751  0.692 0.307 0.692 0.754 
           
 
These three techniques for feature selection place the accurate number of attributes for solving 
this problem between 20 and 27. There are hardly differences in the AUC-ROC between them; in 
order to select the best technique and model we are going to observe the combination of AUCROC, 
false positive rate and feature number combination, to assert that the 20 first variables in the mSVM-
RFE ranking are the best subset of attributes to solve this problem. As you can see in Table 5, the 
final model contains the following embedded and non-embedded Tls: eShl, eSh2, eTr2, eTr3, eTr4, 
eTr5, eX5, eH, eJ, eS, Sh0, Shl, Tr0, Tr2, W, J, S6, X0, X1R, X5. 
4. DISCUSSION 
This paper presents the first theoretical model designed to identify proteins that have transport 
activity by using Star Graph Tls obtained from protein amino acid sequences (primary structure). 
SVM seems to be the most accurate model to solve this problem according to the results that reveal 
the effectiveness of this technique in predicting transport proteins. Three different feature selection 
techniques were performed in order to reduce the dimensionality of the problem. There are hardly 
differences in the AUC-ROC between these techniques, but mSVM-RFE gives the best results due to 
the lowest number of variables (20) and false positive rate combination. These results can help in the 
prediction of new drug transporters using peptide amino acid sequences with unknown biological 
functions as a first step of molecular screening in drug metabolism studies.  
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